Under acidic conditions, it transforms into an active structure and combines with the SH group of the proton pump ((HK)-ATPase), thereby inhibiting the activity of the enzyme and inhibiting gastric acid secretion; it can inhibit the (HK)-ATPase activity of microsomes in dog gastric mucosa; it has an inhibitory effect on the acid secretion of dog gastric mucosal parietal cells stimulated by histamine, acetylcholine and gastrin; it can significantly inhibit the acid secretion caused by gastrin or insulin in healthy adults, the nocturnal gastric acid secretion and the 24-hour gastric acid secretion; it has a significant and sustained inhibitory effect on the gastric acid secretion of rats and gastric pouch dogs; it can promote the healing of chronic gastric and duodenal ulcers in rats, and has a significant inhibitory effect on gastric ulcers, duodenal ulcers and reflux esophagitis caused by various reasons.

Under acidic conditions, it transforms into an active structure and combines with the SH group of the proton pump ((HK)-ATPase) to inhibit gastric acid secretion; it can inhibit (HK)-ATPase activity, parietal cell acid production, gastric acid secretion caused by various stimuli (such as gastrin, insulin, etc.), nighttime and 24-hour gastric acid secretion; it promotes the healing of chronic ulcers and inhibits ulcer formation; it has a significant inhibitory effect on reflux esophagitis.

Inhibit the activity of α-glucosidase in the intestinal wall cells, delay the degradation of ingested carbohydrates, and thus reduce postprandial blood sugar levels

This product is an oral hypoglycemic drug. Its mechanism of hypoglycemic effect is to inhibit the activity of a-glucosidase in the small intestinal wall cells, delay the degradation of ingested carbohydrates, and thus reduce postprandial blood sugar levels.